Is Mineralys Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: MLYS) stock is to Buy MLYS stock.
Out of 1 analyst, 0 (0%) are recommending MLYS as a Strong Buy, 1 (100%) are recommending MLYS as a Buy, 0 (0%) are recommending MLYS as a Hold, 0 (0%) are recommending MLYS as a Sell, and 0 (0%) are recommending MLYS as a Strong Sell.
According to 1 Wall Street analyst that have issued a 1 year MLYS price target, the average MLYS price target is $37.00, with the highest MLYS stock price forecast at $37.00 and the lowest MLYS stock price forecast at $37.00.
The Wall Street analyst predicted that Mineralys Therapeutics's share price could reach $37.00 by Aug 8, 2024. The average Mineralys Therapeutics stock price prediction forecasts a potential upside of 305.26% from the current MLYS share price of $9.13.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.